Together with the known role of IL-9 in CD8 T cells in cancer, these studies suggest that IL-9 responses rescued by anti-PD-1 treatment contribute to the effect of anti-PD-1 therapy by promoting anti-tumor CD8 responses (Figure 1). This evidence concerns the gene CD8A and cancer.